SLDB Q3 2021 Earnings — Solid Biosciences Inc. Revenue & Financial Results | Market Cap Arena

SLDBSolid Biosciences Inc.

$581M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M

Gross Profit

$4M100.0% margin

Operating Income

-$18M-509.8% margin

Net Income

-$18M-508.4% margin

EPS (Diluted)

$-2.40

QoQ Revenue Growth

-1.6%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$19M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$249M

Total Liabilities

$26M

Stockholders' Equity

$223M

Cash & Equivalents

$110M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$0	—
Gross Profit	$4M	$0	—
Operating Income	-$18M	-$21M	+15.1%
Net Income	-$18M	-$21M	+15.4%